ALNOV:EPA
Novacyt SA
€0.37
arrow_upward
+4.23%(+0.015) 1 天
4月29日, GMT+2 17:35:18 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ALNOV 生成关键数据洞见…
开盘价
€0.36
最高价
€0.38
最低价
€0.35
市值
二六四七.七八万
平均成交量
一〇.八六万
成交量
一八.〇六万
52 周最高价
€0.74
52 周最低价
€0.35
每股收益
-€0.50
流通股数
七二五八.八一万
员工人数
二三四
新闻报道
来自全网
Simply Wall Street
·
22分钟前
Alliance Resource Partners (ARLP) Earnings Slide Challenges Bullish Margin And Dividend Narratives
ChartMill
·
35分钟前
Wednesday's session: top gainers and losers
资料
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA简介